249565 Results for: "Shop All Science Olympiad Kits"

Sort By

Anti-CD28 Mouse Monoclonal Antibody [clone: CD28.2]

Supplier: Tonbo Biosciences

The CD28.2 antibody reacts with human CD28, a 44 kDa type I surface glycoprotein which acts as a co-stimulatory receptor in support of the T cell receptor (TCR). CD28 exists as a homodimer with specificity for two known ligands, known as B7-1 (CD80) and B7-2 (CD86), which are expressed on activated B cells and antigen-presenting cells. These ligands trigger CD28 signaling in concert with TCR activation to drive T cell proliferation, induce high-level expression of IL-2, impart resistance to apoptosis, and enhance T cell cytotoxicity. The interaction / co-stimulatory signaling between the B7 ligands and CD28 provides crucial communication between T cells and B cells or APCs to coordinate the adaptive immune response. Other members of the CD28 family of receptors include CTLA-4 (CD152), PD-1 (CD279), ICOS and BTLA.

Expand 2 Items

Anti-CD28 Mouse Monoclonal Antibody (PerCP (Peridinin-Chlorophyll Protein Complex)-Cy5.5®) [clone: CD28.2]

Supplier: Tonbo Biosciences

Expand 2 Items

Anti-C-MYC Mouse Monoclonal Antibody [clone: 33]

Supplier: Genetex

The c-Myc protein is a transcription factor, which is encoded by the c-Myc gene on human chromosome 8q24. c-Myc is commonly activated in a variety of tumor cells and plays an important role in cellular proliferation, differentiation, apoptosis and cell cycle progression. The phosphorylation of c-Myc has been investigated and previous studies have suggested a functional association between phosphorylation at Thr58/Ser62 by glycogen synthase kinase 3, cyclin-dependent kinase, ERK2 and C-Jun N-terminal Kinase (JNK) in cell proliferation and cell cycle regulation. Studies also have shown that c-Myc is essential for tumor cell development in vasculogenesis and angiogenesis that distribute blood throughout the cells, and which brought extensive attention in the development of new therapeutic approach for cancer treatment.

Expand 1 Items

P450-Glo CYP2B6 Assay, Promega

Supplier: Promega Corporation

The P450-Glo Screening Systems provide a complete set of reagents for performing luminescent cytochrome P450 assays

Expand 2 Items

Anti-ORAI3 Rabbit Polyclonal Antibody

Supplier: Prosci

Recognizes human ORAI3, also known as Transmembrane protein 142C (TMEM142C), a 31.5 kDa multi-pass membrane protein belonging to the ORAI family. Antigen stimulation of immune cells triggers Ca2+ entry through Ca2+ release-activated Ca2+ (CRAC) channels. CRAC channels are the main pathway for Ca2+ influx in T-cells and promote the immune response to pathogens by activating the transcription factor NFAT. ORAI3 is one of two mammalian homologs of ORAI1, a four- transmembrane spanning protein that is an essential component of CRAC channels. ORAI3, along with ORAI1 and ORAI2, functions as a Ca2+ plasma membrane channel that is gated through interactions with STIM1, the store-activated endoplasmic reticulum Ca2+ sensor. Studies indicate that ORAI3 channels undergo a lesser degree of depotentiation than ORAI1 or ORAI2. Is not expected to cross react with either ORAI1 or ORAI2.

Expand 1 Items

Anti-TIE2 Rabbit Monoclonal Antibody [clone: EPR26540-78]

Supplier: Abcam

Anti-TIE2 antibody [EPR26540-78] is a Rabbit Monoclonal antibody that is used in TIE2 Western Blot. Suitable for Human, Mouse samples. The TIE2 receptor, a tyrosine kinase, is activated by angiopoietins like Ang1 and Ang2, regulating blood vessel formation and stability. Ang1 promotes vessel maturation and stabilization, while Ang2, often upregulated in tumors, can destabilize vessels and promote angiogenesis. The TIE2 pathway influences tumor microenvironment by affecting vascular integrity and immune cell infiltration, impacting tumor growth and metastasis. Tie2-expressing monocytes (TEMs), a subtype of tumor-associated macrophages (TAMs), exhibit a pro-angiogenic function in tumor tissue and are proposed as biomarkers and therapeutic targets for glioma, arthritis, and thrombus recanalization. TIE2 is also a target for anti-angiogenic treatments, and its inhibition may improve outcomes by reducing tumor vascularity and enhancing immune responses.